In Vitro Efficacy Evaluation Services for Brain Tumors
In vitro efficacy evaluation is a critical component in the drug development process, particularly for complex conditions such as brain tumors. Alfa Cytology provides comprehensive in vitro efficacy evaluations that advance the development of innovative therapies for brain tumors.
Introduction to In Vitro Efficacy Evaluation
In vitro assays and diagnostic technologies have developed rapidly in recent years, from gene sequencing, single nucleotide polymorphism (SNP) screening, and point mutation gene diagnosis at the gene level, to various biomarkers at the protein level, to circulating tumor cell detection (CTC) and thin layer liquid-based cytology (TCT) at the cellular level, and to PET/CT at the tissue level. In vitro assays play a vital role and are indispensable tools in the prevention, diagnosis, monitoring, and treatment of brain tumors.
Fig.1 OBSCs allow rapid drug screening of cell lines and uncultured patient tumor tissue. (Breanna M. F., et al., 2021)
Advantages of In Vitro Efficacy Evaluation for Brain Tumor
- Precision Brain Tumor Focus: All models are validated against brain tissue-specific gene expression profiles (RNA-Seq).
- Dynamic Efficacy Tracking: Real-time monitoring of drug response (0-72 hours) using live-cell imaging systems.
- Integrated Multi-Omics Analysis: Pharmacodynamic data + Transcriptomics/Proteomics → Identification of resistance mechanisms & combination therapy targets. Single-cell sequencing (scRNA-Seq) → Resolution of drug selectivity across tumor subpopulations.
- AI-Driven Prediction: Algorithmic models based on historical databases predict in vivo efficacy correlations with high confidence (R² > 0.85).
Our Services
In vitro brain tumor efficacy evaluation assesses candidate drugs' ability to inhibit tumor growth or induce cell death using cultured cells/organoids, generating critical preclinical data. Alfa Cytology leverages advanced in vitro model platforms, specialized technical expertise, and strict adherence to industry standards to deliver high-quality, tailored in vitro evaluation services for brain tumor therapeutics, accelerating the development of novel anti-brain tumor drugs.
Cell Motility Analysis
- Oristm Migration Assay
- Transwell Migration Assay
- Cyst Formation
- Scratch Assay
- Cell Adhesion Assay
Function Research
- Cell Activity/Toxicity
- Cell Cycle
- Cell Regulation
- Tumorsphere Formation Assay
- Microenvironment Interaction
Molecular Biology
- DNA Methylation Analysis
- Gene Expression & Regulation
- Signaling Pathways
- Immunohistochemistry
- MicroRNA Analysis
Immunology Testing
- Immune Cell Isolation & Phenotyping
- Cell Phenotyping
- Cytokine Analysis
- Immune Interactions & Signaling
Cell Proliferation Assays for Brain Tumor
Alfa Cytology delivers standardized in vitro cell proliferation assays for brain tumor, utilizing established cell lines and 3D spheroids with quantitative high-content imaging to provide mechanism-specific compound efficacy data.
| Project |
Content |
Results |
| Cell culture and processing |
Cell culture and drug treatment |
- Raw data
- Data analysis results
- Full experimental report
|
| MTT Assay |
It mainly reflects the energy metabolism of cells and is a simple and accurate method to detect cell proliferation viability. |
Detection of cellular metabolic activity |
| WTS-1 Assay |
It is more stable than XTT and MTS, which makes the experimental results more stable. |
| CCK8 Assay |
It is a rapid and highly sensitive assay based on WST-8 that is widely used for cell proliferation and cytotoxicity. |
| CTL Assay |
A method for the quantitative determination of live cell numbers by measuring intracellular ATP content by chemiluminescence with ultra-high sensitivity and ultra-wide linear range. |
| CFDA SE Assay |
It is a green fluorescent probe widely used in cell proliferation and tracing studies. It does not have fluorescent properties itself, but can permeate the cell membrane and is catalytically decomposed to produce CFSE after freely entering the cell, which has high fluorescence activity to label proteins. |
Detection of DNA synthesis in cells |
| LDH Release Assay |
Quantitative analysis of cytotoxicity can be achieved by detecting the activity of LDH released into the culture medium from cells with ruptured plasma membranes. |
Detection of cellular LDH release |
ADCC Assays for Brain Tumors
ADCC (antibody-dependent cellular cytotoxicity) assays for brain tumors quantify the potency of brain-tropic therapeutic antibodies to engage immune effector cells (e.g., NK cells) and lyse patient-derived brain tumor cells in vitro. These customized assays evaluate critical immunotherapy efficacy by measuring target-specific cytotoxicity within biologically relevant models of the brain tumor microenvironment.
| Target cells |
Effector Cells |
Features |
Applications |
| Cancer cell lines |
Primary PBMC/NK cells |
Close to in vivo immune microenvironment. |
Late functional confirmation of antibody screening. |
| Engineered cell lines overexpressing targets |
Primary PBMC/NK cells |
Close to the true killing effect of human immune cells, the use of overexpressed cell lines for target cells will increase the success rate of the experiment. |
Early screening or late functional confirmation of antibodies. |
| Cancer cell lines/engineered cell lines overexpressing targets |
ADCC reporter cell lines |
Low cost, high reproducibility, and high success rate. |
Antibody early screening, CMC stage quality release. |
ADCP Assays for Brain Tumors
ADCP (antibody-dependent cellular phagocytosis) assays for brain tumors measure the ability of therapeutic antibodies to drive macrophages or other phagocytes to engulf and eliminate patient-derived brain tumor cells in vitro.
| Target cells |
Effector Cells |
Features |
Applications |
| Cancer cell lines |
M1/M2 type macrophages |
The model is closer to the in vivo immune microenvironment. |
Late functional confirmation of antibody screening. |
| Engineered cell line overexpressing target |
M1/M2 type macrophages |
This model is close to the real phagocytosis effect of human-derived macrophages and has a higher success rate. |
Early screening or late functional confirmation of antibodies. |
| Target overexpression-engineered cell lines |
ADCP reporter cell line |
This model has low cost, high reproducibility, and a high success rate. |
Antibody early screening, CMC stage quality release. |
Modeling Services for In Vitro Efficacy Evaluation
Alfa Cytology offers a comprehensive portfolio of in vitro brain tumor models, including patient-derived organoids (PDOs), 3D spheroids, and blood-brain barrier (BBB) co-culture systems, to rigorously assess drug efficacy, penetration, and mechanism of action.
Contact Us
In vitro assays serve as indispensable tools throughout the entire spectrum of brain tumor research, spanning foundational mechanistic studies, differential diagnosis, compound screening, and therapeutic efficacy evaluation. Alfa Cytology provides clients with comprehensive and accurate in vitro assays for brain tumors, please feel free to
contact us to discuss your project details.
Reference
- Breanna M., et al. (2023) A living ex vivo platform for functional, personalized brain cancer diagnosis [J]. Cell Reports Medicine, 4, 6, 101042.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
